Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis
Xinyu Wang
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Search for more papers by this authorRuosu Zhang
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Search for more papers by this authorSailimai Man
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Meinian Institute of Health, Beijing, China
Peking University Health Science Center, Meinian Public Health Institute, Beijing, China
Search for more papers by this authorJun Lv
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Search for more papers by this authorCanqing Yu
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Search for more papers by this authorYuhan Deng
Meinian Institute of Health, Beijing, China
Department of Social Medicine and Health Education, School of Public Health, Peking University, Beijing, China
Search for more papers by this authorCorresponding Author
Bo Wang
Meinian Institute of Health, Beijing, China
Peking University Health Science Center, Meinian Public Health Institute, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Correspondence
Dr. Yuanjie Pang, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Dr. Bo Wang, Meinian Public Health Institute, Health Science Center, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Search for more papers by this authorLiming Li
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Search for more papers by this authorCorresponding Author
Yuanjie Pang
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Correspondence
Dr. Yuanjie Pang, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Dr. Bo Wang, Meinian Public Health Institute, Health Science Center, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Search for more papers by this authorXinyu Wang
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Search for more papers by this authorRuosu Zhang
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Search for more papers by this authorSailimai Man
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Meinian Institute of Health, Beijing, China
Peking University Health Science Center, Meinian Public Health Institute, Beijing, China
Search for more papers by this authorJun Lv
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Search for more papers by this authorCanqing Yu
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Search for more papers by this authorYuhan Deng
Meinian Institute of Health, Beijing, China
Department of Social Medicine and Health Education, School of Public Health, Peking University, Beijing, China
Search for more papers by this authorCorresponding Author
Bo Wang
Meinian Institute of Health, Beijing, China
Peking University Health Science Center, Meinian Public Health Institute, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Correspondence
Dr. Yuanjie Pang, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Dr. Bo Wang, Meinian Public Health Institute, Health Science Center, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Search for more papers by this authorLiming Li
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Search for more papers by this authorCorresponding Author
Yuanjie Pang
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China
Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China
Correspondence
Dr. Yuanjie Pang, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Dr. Bo Wang, Meinian Public Health Institute, Health Science Center, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Email: [email protected]
Search for more papers by this authorHandling Editor: Luca Valenti
Abstract
Background & Aims
Non-alcoholic fatty liver disease (NAFLD) and the newly proposed metabolic-associated fatty liver disease (MAFLD) were each associated with subclinical atherosclerosis. However, there is limited evidence on risk of atherosclerosis in individuals who meet the criteria for one but not the other. We aimed to investigate the associations of MAFLD or NAFLD status with site-specific and multiple-site atherosclerosis.
Methods
This is a prospective cohort study involving 4524 adults within the MJ health check-up cohort. Logistic regression model was used to estimate odds ratios (ORs) and confidence intervals (CIs) for subclinical atherosclerosis (elevated carotid intima-media thickness [CIMT], carotid plaque [CP], coronary artery calcification [CAC] and retinal atherosclerosis [RA]) associated with MAFLD or NAFLD status, MAFLD subtypes and fibrosis status.
Results
MAFLD was associated with higher risks of elevated CIMT, CP, CAC and RA (OR: 1.41 [95% CI 1.18–1.68], 1.23 [1.02–1.48], 1.60 [1.24–2.08], and 1.79 [1.28–2.52], respectively), whereas NAFLD per se did not increase risk of atherosclerosis except for elevated CIMT. Individuals who met both definitions or the definition for MAFLD but not NAFLD had higher risk of subclinical atherosclerosis. Among MAFLD subtypes, MAFLD with diabetes had the highest risk of subclinical atherosclerosis, but the associations did not differ by fibrosis status. Stronger positive associations were observed of MAFLD with multiple-site than single-site atherosclerosis.
Conclusions
In Chinese adults, MAFLD was associated with subclinical atherosclerosis, with stronger associations for multiple-site atherosclerosis. More attention should be paid to MAFLD with diabetes, and MAFLD might be a better predictor for atherosclerotic disease than NAFLD.
CONFLICT OF INTEREST STATEMENT
The authors have no relevant financial or non-financial interests to disclose.
Supporting Information
| Filename | Description |
|---|---|
| liv15591-sup-0001-Tables.docxWord 2007 document , 454.2 KB |
Table S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; 158(7): 1999-2014.
- 2Wai-Sun Wong V, Kanwal F. On the proposed definition of metabolic-associated fatty liver disease. Clin Gastroenterol and Hepatol. 2021; 19(5): 865-870.
- 3Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73-84.
- 4Willeit P, Tschiderer L, Allara E, et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk. Circulation. 2020; 142(7): 621-642.
- 5Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018; 72(4): 434-447.
- 6Polak JF, Szklo M, Kronmal RA, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013; 2(2). doi:10.1161/JAHA.113.000087
- 7Laclaustra M, Casasnovas JA, Fernández-Ortiz A, et al. Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol. 2016; 67(11): 1263-1274.
- 8Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021; 75(6): 1284-1291.
- 9Pais R, Redheuil A, Cluzel P, Ratziu V, Giral P. Relationship among fatty liver, specific and multiple-site atherosclerosis, and 10-year Framingham score. Hepatology. 2019; 69(4): 1453-1463.
- 10Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016; 151(3): 481-488.
- 11Targher G. Non-alcoholic fatty liver disease as driving force in coronary heart disease? Gut. 2017; 66(2): 213-214.
- 12Park HE, Kwak MS, Kim D, Kim MK, Cha MJ, Choi SY. Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study. J Clin Endocrinol Metab. 2016; 101(8): 3134-3143.
- 13Liu S, Wang J, Wu S, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021; 120:154779.
- 14Wang J, Liu S, Cao Q, et al. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study. Front Med. 2022; 16: 714-722. doi:10.1007/s11684-021-0888-8
- 15Lin TY, Chen YJ, Chen WL, Peng TC. The relationship between nonalcoholic fatty liver disease and retinopathy in NHANES III. PLoS One. 2016; 11(11). doi:10.1371/journal.pone.0165970
- 16Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3): 745-750.
- 17Man S, Lv J, Yu C, et al. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol Int. 2022; 16: 1412-1423. doi:10.1007/s12072-022-10395-8
- 18Fan JG, Wei L, Zhuang H, et al. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis. 2019; 20(4): 163-173.
- 19Lee H, Lim TS, Kim SU, Kim HC. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol Int. 2022; 16: 1308-1317. doi:10.1007/s12072-022-10407-7
- 20Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7(10): 1104-1112.
- 21Johnston PM, Patel J, Byrne DC. Causes of mortality in non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD). Curr Pharm Des. 2020; 26(10): 1079-1092.
- 22Song P, Fang Z, Wang H, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020; 8(5): e721-e729. doi:10.1016/S2214-109X(20)30117-0
- 23Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. Eur J of Prev Cardiol. 2020; 27(4): 394-406.
- 24Wang X, Cheng S, Lv J, et al. Liver biomarkers, genetic and lifestyle risk factors in relation to risk of cardiovascular disease in Chinese. Front Cardiovasc Med. 2022; 9:938902.
- 25Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the multi-ethnic study of atherosclerosis (MESA). Arch Intern Med. 2008; 168(12): 1333-1339.
- 26Gepner AD, Young R, Delaney JA, et al. Comparison of carotid plaque score and coronary artery calcium score for predicting cardiovascular disease events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2017; 6(2):e005179. doi:10.1161/JAHA.116.005179
- 27Zhou YY, Zhou XD, Wu SJ, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun. 2018; 2(4): 376-392.
- 28Yang W, Xu H, Yu X, Wang Y. Association between retinal artery lesions and nonalcoholic fatty liver disease. Hepatol Int. 2015; 9(2): 278-282.
- 29Yu X, Chen C, Guo Y, et al. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. Ann Med. 2021; 53(1): 1621-1631.
- 30Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11): 1410-1422.
- 31Brunt EM, Wong VWS, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015; 1(1):15080.
- 32Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54(3): 1082-1090.
- 33Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018; 68(2): 305-315.
Author names in bold designate shared co-first authorship.
Citing Literature
